Pegvisomant: a growth hormone receptor antagonist for the treatment of acromegaly.
Affiliation
Department of Endocrinology, Christie Hospital, Manchester, UK.Issue Date
2000-04
Metadata
Show full item recordAbstract
Growth hormone receptor (GHR) dimerization is a prerequisite to the generation of growth hormone (GH) action. Pegvisomant is a GHR antagonist that has been designed to bind to the GHR at the cell surface and hence block this process. Initial studies suggest that pegvisomant is a highly effective antagonist of GH action in patients with acromegaly. The blockade of GH action, rather than the inhibition of pituitary GH secretion, represents a novel concept in the medical management of acromegaly. In this review, the design, efficacy, challenges and future role of pegvisomant are discussed.Citation
Pegvisomant: a growth hormone receptor antagonist for the treatment of acromegaly. 2000, 10 Suppl B:S119-23 Growth Horm. IGF Res.Journal
Growth Hormone & IGF ResearchPubMed ID
10984267Type
ArticleLanguage
enISSN
1096-6374Collections
Related articles
- Growth hormone receptor antagonists therapy for acromegaly.
- Authors: Parkinson C, Trainer PJ
- Issue date: 1999 Oct
- Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly.
- Authors: Kopchick JJ, Parkinson C, Stevens EC, Trainer PJ
- Issue date: 2002 Oct
- Pegvisomant in the treatment of acromegaly.
- Authors: Parkinson C, Scarlett JA, Trainer PJ
- Issue date: 2003 Sep 26
- Pegvisomant: a growth hormone receptor antagonist used in the treatment of acromegaly.
- Authors: Tritos NA, Biller BM
- Issue date: 2017 Feb
- Metabolic effects of GH antagonism in patients with acromegaly.
- Authors: Trainer PJ
- Issue date: 2003 Aug